TNGX Stock — Tango Therapeutics Inc.: Cash, EV, Pipeline

Share price

$21.75

Market cap

$3,667.3M

Cash

$1,014.0M

Enterprise value

$2,653.3M

Balance sheet

Cash	$1,014.0M
Debt	$0.0M
Net cash	$1,014.0M
Enterprise value	$2,653.3M
Basic shares	168.4M shares
Fully diluted shares	178.3M shares
Fully diluted market cap	$3,876.9M
Cash per share	$6.02

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading TNGX daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Oct 13 - Nov 24	TNG260	Phase 2	Non Small Cell Lung Cancer; Solid Tumors, Adult; Lung Cancer	—
May 12 - Jun 23	TNG456	Phase 2	Non Small Cell Lung Cancer; Glioma Glioblastoma Multiforme; Glioma, Malignant	2H 2026
Jun 12 - Jul 24	S095035	Phase 2	MTAP-deleted Solid Tumors	—
Jul 13 - Aug 24	TNG462	Phase 2	Locally Advanced Solid Tumor	—
Jul 13 - Aug 24	TNG462	Phase 2	PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; NSCLC	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

vopimetostat

Phase 1 · Active Modality: small molecule (MTA-cooperative PRMT5 inhibitor; MTAP-deletion synthetic lethal)

Aliases TNG462

Target PRMT5

Partnerships Revolution Medicines: Nov 2024 CTCSA (daraxonrasib + zoldonrasib supply for vopimetostat combo; Tango sponsors; non-exclusive). Erasca: Mar 2026 CTCSA (ERAS-0015 supply for vopimetostat + ERAS-0015 Phase 1/2; Tango sponsors; non-exclusive)

Indications

MTAP-deleted pancreatic cancer (monotherapy and RAS-inhibitor combos) (Phase 1)
MTAP-deleted lung cancer (Phase 1)
MTAP-deleted cancers, histology-selective (excluding sarcoma, pancreatic, lung) (Phase 1)

Catalysts

— 2026
— 2026
— H2 2026

Status note Phase 1/2 ongoing; 2L pivotal trial in MTAP-deleted pancreatic cancer planned for 2026; registrational path for vopimetostat + daraxonrasib under development with Revolution Medicines.

TNG456

Phase 1 · Active Modality: small molecule (brain-penetrant MTA-cooperative PRMT5 inhibitor)

Target PRMT5

Indications

MTAP-deleted solid tumors, including glioblastoma (Phase 1)

Catalysts

— 2026

Status note First patient treated May 2025; dose escalation enrolling.

TNG961

Preclinical · Active Modality: small molecule (molecular glue degrader of HBS1L)

Target HBS1L

Indications

FOCAD-deleted/MTAP-deleted solid tumors (Preclinical)

Status note Development candidate; IND-enabling phase.

TNG260

Phase 1 · Active Modality: small molecule (CoREST inhibitor)

Target CoREST

Indications

Checkpoint inhibitor-resistant STK11-mutant / KRAS wild-type NSCLC (in combination with pembrolizumab) (Phase 1)

Status note 80 mg QD selected for dose expansion, ongoing.

Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	TNG456
Lead indication	Non Small Cell Lung Cancer
Lead phase	Phase 2
Active trials	4
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06810544	Phase 2	Recruiting	Sponsor	TNGX	LLY	Non Small Cell Lung Cancer; Glioma Glioblastoma Multiforme; Glioma, Malignant	2H 2026
NCT05732831	Phase 2	Recruiting	Sponsor	TNGX	—	Locally Advanced Solid Tumor	—
NCT06922591	Phase 2	Recruiting	Sponsor	TNGX	—	PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; NSCLC	—
NCT05887492	Phase 2	Active, not recruiting	Sponsor	TNGX	—	Non Small Cell Lung Cancer; Solid Tumors, Adult; Lung Cancer	—
NCT06188702	Phase 2	Active, not recruiting	Collaborator	Servier Bio-Innovation LLC	—	MTAP-deleted Solid Tumors	—

Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 5 active trials for Tango Therapeutics, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
RTW Investments	13,900,620	+600,000	3.71%	2026-08-14
Logos Global Management	2,850,000	-150,000	3.84%	2026-08-14
Baker Bros. Advisors	333,333	+333,333	0.05%	2026-08-14
Sphera Biotech	254,250	-89,313	1.14%	2026-08-14
ADAR1 Capital Management	76,761	+26,761	0.11%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

TNGX — Tango Therapeutics Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders